ERC Consolidator Grant · 2025
Visceral leishmaniasis (VL), a neglected tropical disease caused by Leishmania parasites, forms a significant health challenge in the Indian subcontinent and Eastern Africa. Despite substantial progress towards elimination, critical challenges persist in the ‘last mile’ to achieve and maintain elimination. I propose the innovative 5-year TRANSPHORM project, where I will develop novel pharmacological strategies to prevent Leishmania transmission and control sand fly vectors. Patients with the skin infection post-kala-azar dermal leishmaniasis (PKDL) are one of the main transmission reservoirs for VL in India. We will examine how treatment can be more focused on reducing the infectiousness of…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.